Another turn of the screw for EU drug safety monitoring
This article was originally published in SRA
Companies operating in Europe will face an even tougher drug safety monitoring environment next year when new pharmacovigilance laws just adopted at EU level take effect.
You may also be interested in...
The EU’s new health commissioner, Stella Kyriakides, has outlined the commission’s plans for dealing with medicines access issues in the EU member states. They include completing the review of the EU pediatric and orphan legislation and developing a new strategic plan to tackle shortages and affordability problems next year.
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.
As stockpiles of Ebola vaccine are being built up around the world, Médecins sans Frontières has said more action is needed to ensure sufficient numbers of vaccinations are available for use in current and future outbreaks.